EUVIMEDEUVIMED entdecken
Open Access

Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy

Maria C Foss-Freitas, Salman Imam, Adam Neidert, Anabela Dill Gomes, David T Broome, Elif A Oral iD

Diabetes Care · 01.04.2024 · 47 (4) · 653-659

DOI: 10.2337/dc23-1614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 01.02.2024. Verfasst von Maria C Foss-Freitas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Lipodystrophy, Familial Partial, Pancreatitis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, Caswell Diabetes Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Glucagon-like peptide 1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus (DM), but their efficacy in familial partial lipodystrophy (FPLD) is unknown. In this retrospective study, we evaluated the effect of GLP-1RA in patients with FPLD. RESEARCH DESIGN AND METHODS We analyzed data, reported with SDs, from 14 patients with FPLD (aged 58 ± 12 years; 76.47% female) and 14 patients with type 2 DM (aged 58 ± 13 years; 71% female) before and 6 months after starting GLP-1RA. RESULTS We observed reduction in weight (95 ± 23 to 91 ± 22 kg; P = 0.002), BMI (33 ± 6 to 31 ± 6 kg/m2; P = 0.001), HbA1c (8.2% ± 1.4% to 7.7% ± 1.4%; P = 0.02), and fasting glucose (186 ± 64 to 166 ± 53 mg/dL; P = 0.04) in patients with FPLD. The change in triglycerides after treatment was greater in the FPLD group compared with the DM group (P = 0.02). We noted acute pancreatitis in two case subjects with FPLD with longer therapy. CONCLUSIONS Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipodystrophy, Familial PartialPancreatitisDiabetes Mellitus, Type 2HumansFemaleMaleHypoglycemic AgentsRetrospective StudiesBlood GlucoseAcute DiseaseGlycated HemoglobinGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Substanzen

Hypoglycemic AgentsBlood GlucoseGlycated HemoglobinGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI.
  • Mercy Health Anderson Hospital (Family Medicine Residency), Cincinnati, OH.

ORCID-Profile: Elif A Oral

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • Caswell Diabetes Institute
  • NIH

Zitieren

APA

Foss-Freitas, M. C., Imam, S., Neidert, A., Gomes, A. D., Broome, D. T., & Oral, E. A. (2024). Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care, 47(4), 653-659. https://doi.org/10.2337/dc23-1614

Vancouver

Foss-Freitas MC, Imam S, Neidert A, Gomes AD, Broome DT, Oral EA. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care. 2024;47(4):653-659. doi:10.2337/dc23-1614

BibTeX
@article{FossFreitas2024,
  author = {Foss-Freitas, Maria C and Imam, Salman and Neidert, Adam and Gomes, Anabela Dill and Broome, David T and Oral, Elif A},
  title = {Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy},
  journal = {Diabetes Care},
  year = {2024},
  volume = {47},
  number = {4},
  pages = {653--659},
  doi = {10.2337/dc23-1614}
}
Kostenlos starten →